Loading…
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-32M | $-34M | $-33M | -76.5% | - | -39.4% |
| 2024 | $0M | $-54M | $-56M | $-43M | -78.7% | - | 48.8% |
| 2023 | $0M | $-35M | $-38M | $-30M | -31.3% | - | -39.5% |
| 2022 | $0M | $-60M | $-62M | $-57M | -41.1% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 62.68 | 42.79 | 60.12 | 35.27 |
| Research And Development | - | 47.31 | 29.46 | 48.22 | 25.66 |
| Selling General And Administration | - | 15.37 | 13.34 | 11.89 | 9.60 |
| Total Expenses | - | 62.68 | 42.79 | 60.12 | 35.27 |
| Operating Income | - | -62.68 | -42.79 | -60.12 | -35.27 |
| Total Operating Income As Reported | - | -62.68 | -42.79 | -60.12 | -35.27 |
| EBITDA | - | -60.07 | -35.21 | -53.68 | -31.69 |
| Normalized EBITDA | - | -60.07 | -35.21 | -53.68 | -31.69 |
| EBIT | - | -60.33 | -35.47 | -53.93 | -31.94 |
| Interest Income | - | 2.35 | 7.32 | 6.19 | 3.32 |
| Interest Expense | - | 1.69 | 2.07 | 1.93 | 1.91 |
| Net Interest Income | - | 0.66 | 5.25 | 4.27 | 1.42 |
| Interest Income Non Operating | - | 2.35 | 7.32 | 6.19 | 3.32 |
| Interest Expense Non Operating | - | 1.69 | 2.07 | 1.93 | 1.91 |
| Net Non Operating Interest Income Expense | - | 0.66 | 5.25 | 4.27 | 1.42 |
| Pretax Income | - | -62.02 | -37.54 | -55.85 | -33.85 |
| Tax Provision | 0 | - | - | - | - |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -62.02 | -37.54 | -55.85 | -33.85 |
| Net Income From Continuing And Discontinued Operation | - | -62.02 | -37.54 | -55.85 | -33.85 |
| Net Income From Continuing Operation Net Minority Interest | - | -62.02 | -37.54 | -55.85 | -33.85 |
| Net Income | - | -62.02 | -37.54 | -55.85 | -33.85 |
| Net Income Common Stockholders | - | -62.02 | -37.54 | -55.85 | -33.85 |
| Net Income Including Noncontrolling Interests | - | -62.02 | -37.54 | -55.85 | -33.85 |
| Normalized Income | - | -62.02 | -37.54 | -55.85 | -33.85 |
| Diluted NI Availto Com Stockholders | - | -62.02 | -37.54 | -55.85 | -33.85 |
| Basic Average Shares | - | 58.41 | 58.94 | 59.48 | 60.06 |
| Diluted Average Shares | - | 58.41 | 58.94 | 59.48 | 60.06 |
| Reconciled Depreciation | - | 0.26 | 0.26 | 0.25 | 0.25 |
| Total Unusual Items | 0 | - | - | - | - |
| Total Unusual Items Excluding Goodwill | 0 | - | - | - | - |
| Special Income Charges | 0 | - | - | - | - |
| General And Administrative Expense | - | 15.37 | 13.34 | 11.89 | 9.60 |
| Other Gand A | - | 15.37 | 13.34 | 11.89 | 9.60 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Aldeyra Therapeutics, Inc.this co. | ALDX | $106M | -3.14 | 2.40 | -76.5% | -1.63 |
| The Joint Corp. | JYNT | $117M | 40.32 | 7.80 | 19.3% | 118.19 |
| Cardiff Oncology, Inc. | CRDF | $106M | -2.31 | 2.33 | -101.0% | -1.86 |
| Neuronetics, Inc. | STIM | $102M | -2.61 | 4.54 | -174.3% | -5.84 |
| OptimizeRx Corporation | OPRX | $101M |
| - |
| - |
| - |
| - |
| 19.67 |
| 0.79 |
| 4.0% |
| 6.26 |
| Definitive Healthcare Corp. | DH | $96M | -0.69 | 0.34 | -49.4% | -0.74 |
| Heron Therapeutics, Inc. | HRTX | $92M | - | 6.39 | -141.0% | - |
| Outset Medical, Inc. | OM | $88M | -1.07 | 0.69 | -64.3% | -2.46 |
| Aardvark Therapeutics, Inc. | AARD | $86M | -1.49 | 0.81 | -54.0% | -0.63 |
| Peer Median | - | -1.07 | 1.57 | -59.2% | -0.74 | |